氢溴酸山莨菪碱对缺血性结肠炎的疗效观察OA
Observation on the efficacy of anisodamine hydrobromide in ischemic colitis
目的 观察氢溴酸山莨菪碱(Ani-HBr)对缺血性结肠炎(IC)的治疗效果.方法 选择非坏疽型 IC 患者 124 例,随机均分为对照组(常规 IC 治疗)和观察组(常规 IC 治疗+Ani-HBr 静脉滴注).比较两组患者的结肠黏膜表现、转手术治疗率、治疗有效率、实验室指标(C 反应蛋白、D-二聚体、纤维蛋白原、白蛋白、前白蛋白)和安全性指标.结果 观察组便血消失、腹痛缓解、肠功能恢复及住院时间均短于对照组(P<0.05);治疗后,两组的 Mayo 评分均降低,且观察组低于对照组(P<0.05);观察组的内镜应答率和黏膜愈合率高于对照组(P<0.05);与对照组比较,观察组的转手术治疗率较低、总有效率较高(P<0.05);治疗后,两组的 C 反应蛋白、D-二聚体和纤维蛋白原水平均降低,且观察组低于对照组(P<0.05);两组白蛋白、前白蛋白水平均升高,且观察组高于对照组(P<0.05);两组不良反应发生率比较,差异无显著性(P>0.05);出院1 年内,观察组的IC 复发率低于对照组(P<0.05).结论 Ani-HBr 可有助于减轻结肠黏膜损伤,改善炎症、营养和凝血状态,促进 IC 症状缓解,缩短患者的功能恢复和住院时间,降低复发风险,在 IC 的临床治疗中具有良好效果和安全性.
Aim To observe the therapeutic effect of anisodamine hydrobromide(Ani-HBr)on ischemic colitis(IC).Methods A total of 124 patients with non-gangrenous IC were selected and randomly divided into a control group(conventional IC treatment)and an observation group(conventional IC treatment+intravenous Ani-HBr).These two groups were compared in terms of colonoscopy findings,rate of surgical conversion,treatment response rate,laboratory parameters(C-reactive protein,D-D,fibrino-gen,albumin,and prealbumin),and safety indicators.Results The times to resolution of hematochezia,relief of abdominal pain,recovery of bowel function,and hospital stay were shorter in the observation group than those in the control group(P<0.05).After treatment,Mayo scores decreased in both groups,with a lower score in the observation group(P<0.05).The rates of endo-scopic response and mucosal healing were higher in the observation group than those in the control group(P<0.05).Compared with the control group,the observation group had a lower rate of surgical conversion and a higher overall response rate(P<0.05).After treatment,levels of C-reactive protein,D-D,and fibrinogen decreased in both groups,with lower levels in the observation group(P<0.05);levels of albumin and prealbumin increased in both groups,with higher levels in the observation group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Within one year after dis-charge,the recurrence rate of IC was lower in the observation group than those in the control group(P<0.05).There was no statisti-cally significant difference in the total incidence of adverse reactions between the thumbtack needle group and the control group(P>0.05).Conclusion Ani-HBr can help alleviate colonic mucosal injury,improve inflammatory,nutritional,and coagulation sta-tus,promote symptom relief of IC,shorten functional recovery and hospital stay,and reduce the risk of recurrence,demonstrating good efficacy and safety in the clinical treatment of IC.
吴晓云;靳海峰;边振光;冯佳;李阳;刘贞
中国人民解放军联勤保障部队第九八〇医院消化内科,河北 石家庄 050082中国人民解放军联勤保障部队第九八〇医院消化内科,河北 石家庄 050082中国人民解放军联勤保障部队第九八〇医院消化内科,河北 石家庄 050082中国人民解放军联勤保障部队第九八〇医院消化内科,河北 石家庄 050082中国人民解放军联勤保障部队第九八〇医院消化内科,河北 石家庄 050082中国人民解放军联勤保障部队第九八〇医院消化内科,河北 石家庄 050082
医药卫生
缺血性结肠炎氢溴酸山莨菪碱M胆碱受体阻断药
ischemic colitisanisodamine hydrobromideM cholinergic receptor blockers
《中南医学科学杂志》 2026 (3)
435-438,4
河北省卫健委课题(20251056)
评论